-
1 Comment
CASI Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 38.0% below its 200 day moving average.
From a valuation standpoint, the stock is 98.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 15.7.
CASI Pharmaceuticals, Inc's total revenue rose by 258.8% to $5M since the same quarter in the previous year.
Its net income has increased by 99.9% to $-13K since the same quarter in the previous year.
Finally, its free cash flow fell by 47.5% to $-19M since the same quarter in the previous year.
Based on the above factors, CASI Pharmaceuticals, Inc gets an overall score of 3/5.
| Sector | Healthcare |
|---|---|
| Industry | Biotechnology |
| Exchange | NASDAQ |
| CurrencyCode | USD |
| ISIN | US14757U1097 |
| Beta | 0.61 |
|---|---|
| Market Cap | 31M |
| PE Ratio | None |
| Target Price | 4 |
| Dividend Yield | None |
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc"RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CASI using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
